Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8924397 | 0.83 | IMPDH2 (0.40) | IMPDH2IMPDH1 | |
| SCHEMBL5086099 | 0.82 | CA1 (0.30) | — | |
| SCHEMBL13866596 | 0.76 | CA2 (0.31) | — | |
| SCHEMBL17431561 | 0.76 | IMPDH2 (0.37) | TDP1IMPDH2IGF1RSRCAXL | |
| SCHEMBL5145143 | 0.76 | — | — | |
| SCHEMBL12143217 | 0.74 | TDP1 (0.46) | TDP1IMPDH2 | |
| SCHEMBL4559180 | 0.73 | APP (0.51) | IMPDH2ALOX5 | |
| SCHEMBL14458460 | 0.73 | IMPDH2 (0.33) | IMPDH2IMPDH1 | |
| SCHEMBL2029504 | 0.73 | IMPDH2 (0.33) | IMPDH2IMPDH1 | |
| SCHEMBL14089301 | 0.72 | TDP1 (0.40) | TDP1IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102775290-B | 2-chloromethyl-5,6-dimethoxy-3-methyl isophthalic acid, the preparation method of 4-para benzoquinone | KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-08-26 | — | — | CN | claimed |
| US-7528271-B2 | Intermediates, process for their preparation and synthesis of 1,4-benzoquiones | BERGEN TEKNOLOGIOVERFORING AS (NO) | 2009-05-05 | — | — | US | disclosed |
| WO-2008140328-A2 | NOVEL INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND SYNTHESIS OF 1,4-BENZOQUINONES | BERGEN TEKNOLOGIOVERFORING AS (NO) | 2008-11-20 | — | — | WO | disclosed |
| US-20080287702-A1 | Novel intermediates, process for their preparation and synthesis of 1, 4-benzoquiones | BERGEN TEKNOLOGIOVERFORING AS (NO) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287702-A1 | Novel intermediates, process for their preparation and synthesis of 1, 4-benzoquiones | SQOR, NDUFB10, UQCRB | TDP1 3338/4885IMPDH2 2086/4885IGF1R 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.